Skip to main content
Erschienen in: Diabetologia 7/2004

01.07.2004 | Article

Mutation at position −132 in the islet amyloid polypeptide (IAPP) gene promoter enhances basal transcriptional activity through a new CRE-like binding site

verfasst von: A. Novials, E. Mato, M. Lucas, C. Franco, M. Rivas, P. Santisteban, R. Gomis

Erschienen in: Diabetologia | Ausgabe 7/2004

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Mutations in the islet amyloid polypeptide (IAPP) gene may play a potential role in the abnormal regulation or expression of the peptide. The aim of this study was to determine the functional role of the −132 G/A mutation reported in the promoter region of the IAPP gene in a population of Spanish Type 2 diabetic patients.

Methods

We investigated the transcriptional activity using MIN6 cells and luciferase reporter plasmids in several culture conditions. Key regulatory elements of the IAPP promoter region were also analysed by electrophoretic mobility shift assays (EMSA).

Results

The mutant construct doubled IAPP transcriptional activity (p<0.001). Both constructs showed severely reduced promoter activity (four-fold decrease) in the presence of verapamil and diazoxide. In contrast, IAPP promoter activity was doubled after incubation with forskolin or dexamethasone, regardless of the glucose concentrations in the culture media. EMSA revealed that the −132 G/A mutation increased the binding affinity through two DNA-protein complexes. In addition, a cAMP-responsive element binding protein (CREB) was identified by super-shift EMSA.

Conclusions/interpretation

Our studies show that the wild-type and the mutant constructs are regulated in a similar pattern under all conditions, strongly indicating that the −132 G/A mutation increases basal but not inducible transcription. These results may be explained by new binding to the mutant region through CREB and other transcription factors not yet identified.
Literatur
1.
Zurück zum Zitat Cooper GJS, Willis AC, Clark A, Turner RC, Sim R, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of Type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632CrossRefPubMedPubMedCentral Cooper GJS, Willis AC, Clark A, Turner RC, Sim R, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of Type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628–8632CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Nishi M, Sanke T, Nagamatsu S, Bell GI, Steiner DF (1990) Islet amyloid polypeptide: a new-cell secretory product related to islet amyloid deposits. J Biol Chem 265:4173–4176PubMed Nishi M, Sanke T, Nagamatsu S, Bell GI, Steiner DF (1990) Islet amyloid polypeptide: a new-cell secretory product related to islet amyloid deposits. J Biol Chem 265:4173–4176PubMed
3.
Zurück zum Zitat Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881–3885CrossRefPubMedPubMedCentral Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881–3885CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Clark A, Wells C, Buley ID et al. (1988) Islet amyloid, increased A-cells, reduced beta-cells and exocrine fibrosis: quantitative changes in the pancreas in Type 2 diabetes. Diabetes Res 9:151–159PubMed Clark A, Wells C, Buley ID et al. (1988) Islet amyloid, increased A-cells, reduced beta-cells and exocrine fibrosis: quantitative changes in the pancreas in Type 2 diabetes. Diabetes Res 9:151–159PubMed
5.
Zurück zum Zitat Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long recognized but underappreciated pathological feature of Type 2 diabetes. Diabetes 48:241–253CrossRefPubMed Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long recognized but underappreciated pathological feature of Type 2 diabetes. Diabetes 48:241–253CrossRefPubMed
6.
Zurück zum Zitat Höppener JW, Ahrén B, Lips CJM (2000) Islet amyloid and Type 2 diabetes mellitus. N Engl J Med 343:411–419CrossRef Höppener JW, Ahrén B, Lips CJM (2000) Islet amyloid and Type 2 diabetes mellitus. N Engl J Med 343:411–419CrossRef
7.
Zurück zum Zitat Westermark P, Engstrom U, Johnson KH, Westermark GT, Betscholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036–5045CrossRefPubMedPubMedCentral Westermark P, Engstrom U, Johnson KH, Westermark GT, Betscholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036–5045CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Castillo GM, Cummings JA, Yang W et al. (1998) Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan’s enhancement of islet amyloid polypetide (amylin) fibril formation. Diabetes 47:612–620CrossRefPubMed Castillo GM, Cummings JA, Yang W et al. (1998) Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan’s enhancement of islet amyloid polypetide (amylin) fibril formation. Diabetes 47:612–620CrossRefPubMed
9.
Zurück zum Zitat DeKoning EJ, Morris ER, Hofhuis FM et al. (1994) Intra and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 91:8467–8471CrossRef DeKoning EJ, Morris ER, Hofhuis FM et al. (1994) Intra and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci USA 91:8467–8471CrossRef
10.
Zurück zum Zitat Verchere CB, D’Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496CrossRefPubMedPubMedCentral Verchere CB, D’Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492–3496CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Janson J, Soeller WC, Roche PC et al. (1996) Spontaneous diabetes mellitus in transgenic mice expressing human amyloid polypeptide. Proc Natl Acad Sci USA 93:7283–7288CrossRefPubMedPubMedCentral Janson J, Soeller WC, Roche PC et al. (1996) Spontaneous diabetes mellitus in transgenic mice expressing human amyloid polypeptide. Proc Natl Acad Sci USA 93:7283–7288CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat German MS, Moss LG, Wang J, Rutter WJ (1992) The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes. Mol Cell Biol 12:1777–1788CrossRefPubMedPubMedCentral German MS, Moss LG, Wang J, Rutter WJ (1992) The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes. Mol Cell Biol 12:1777–1788CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Novials A, Rojas I, Franco C, Casamitjana R, Usac EF, Gomis R (2001) A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with Type II diabetes mellitus. Diabetologia 44:1064–1065CrossRefPubMed Novials A, Rojas I, Franco C, Casamitjana R, Usac EF, Gomis R (2001) A novel mutation in islet amyloid polypeptide (IAPP) gene promoter is associated with Type II diabetes mellitus. Diabetologia 44:1064–1065CrossRefPubMed
14.
Zurück zum Zitat Poa NR, Cooper GJS, Edgar PF (2003) Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 46:574–578CrossRefPubMed Poa NR, Cooper GJS, Edgar PF (2003) Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 46:574–578CrossRefPubMed
15.
Zurück zum Zitat Pildal J, Lajer SK, Almind K et al. (2003) Studies of variability in the islet amyloid polypeptide gene in relation to Type 2 diabetes. Diabetic Med 20:491–494CrossRefPubMed Pildal J, Lajer SK, Almind K et al. (2003) Studies of variability in the islet amyloid polypeptide gene in relation to Type 2 diabetes. Diabetic Med 20:491–494CrossRefPubMed
16.
Zurück zum Zitat Novials A, Kistauri A, Chico A, Gomis R (2003) To: Poa NR, Cooper GJX, Edgar PF: Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 46:574–578. Diabetologia 46:1708–1709CrossRefPubMed Novials A, Kistauri A, Chico A, Gomis R (2003) To: Poa NR, Cooper GJX, Edgar PF: Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 46:574–578. Diabetologia 46:1708–1709CrossRefPubMed
17.
Zurück zum Zitat Ishihara H, Asano T, Tsukuda K et al. (1993) Pancreatic beta-cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36:1139–1145CrossRefPubMed Ishihara H, Asano T, Tsukuda K et al. (1993) Pancreatic beta-cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36:1139–1145CrossRefPubMed
18.
Zurück zum Zitat Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499CrossRefPubMedPubMedCentral Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Santisteban P, Acebrón A, Polycarpou-Schwartz M, Di Lauro R (1992) Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Mol Endocrinol 6:1310–1317PubMed Santisteban P, Acebrón A, Polycarpou-Schwartz M, Di Lauro R (1992) Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Mol Endocrinol 6:1310–1317PubMed
20.
Zurück zum Zitat Gasa R, Gomis R, Casamitjana R, Rivera F, Novials A (1997) Glucose regulation of islet amyloid polypeptide gene expression in rat pancreatic islets. Am J Physiol 272:E543–E549PubMed Gasa R, Gomis R, Casamitjana R, Rivera F, Novials A (1997) Glucose regulation of islet amyloid polypeptide gene expression in rat pancreatic islets. Am J Physiol 272:E543–E549PubMed
21.
Zurück zum Zitat Gasa R, Gomis R, Casamitjana R, Novials A (1997) Signals related to glucose metabolism regulate islet amyloid polypeptide (IAPP) gene expression in human pancreatic islets. Regul Pept 68:99–104CrossRefPubMed Gasa R, Gomis R, Casamitjana R, Novials A (1997) Signals related to glucose metabolism regulate islet amyloid polypeptide (IAPP) gene expression in human pancreatic islets. Regul Pept 68:99–104CrossRefPubMed
22.
Zurück zum Zitat Carty MD, Lillquist JS, Peshavaria M, Stein R, Soeller WC (1997) Identification of cis-and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells. J Biol Chem 272:11986–11993CrossRefPubMed Carty MD, Lillquist JS, Peshavaria M, Stein R, Soeller WC (1997) Identification of cis-and trans-active factors regulating human islet amyloid polypeptide gene expression in pancreatic beta-cells. J Biol Chem 272:11986–11993CrossRefPubMed
23.
Zurück zum Zitat Ekawa K, Nishi M, Ohagi S, Sanke T, Nanjo K (1997) Cloning of mouse islet amyloid polypeptide gene and characterization of its promoter. J Mol Endocrinol 19:79–86CrossRefPubMed Ekawa K, Nishi M, Ohagi S, Sanke T, Nanjo K (1997) Cloning of mouse islet amyloid polypeptide gene and characterization of its promoter. J Mol Endocrinol 19:79–86CrossRefPubMed
24.
Zurück zum Zitat Mcfarlane WM, Campbell SC, Elrick LJ et al. (2000) Glucose regulates islet amyloid polypeptide gene transcription in a PDX1- and calcium-dependent manner. J Biol Chem 275:15330–15335CrossRef Mcfarlane WM, Campbell SC, Elrick LJ et al. (2000) Glucose regulates islet amyloid polypeptide gene transcription in a PDX1- and calcium-dependent manner. J Biol Chem 275:15330–15335CrossRef
25.
Zurück zum Zitat Mosselman S, Höppener JW, With L, Soeller WC, Lips CJM, Jansz HS (1990) IAPP/amylin gene transcriptional control region: evidence for negative regulation. FEBS Lett 271:33–36CrossRefPubMed Mosselman S, Höppener JW, With L, Soeller WC, Lips CJM, Jansz HS (1990) IAPP/amylin gene transcriptional control region: evidence for negative regulation. FEBS Lett 271:33–36CrossRefPubMed
26.
Zurück zum Zitat Ding WQ, Holicky E, Miller J (2001) Glucose and forskolin regulate IAPP gene expression through different signal transduction pathways. Am J Physiol Endocrinol Metab 281:E938–E945PubMed Ding WQ, Holicky E, Miller J (2001) Glucose and forskolin regulate IAPP gene expression through different signal transduction pathways. Am J Physiol Endocrinol Metab 281:E938–E945PubMed
27.
Zurück zum Zitat Koranyi L, Bourey R, Turk J, Mueckler M, Permutt MA (1992) Differential expression of rat pancreatic islet beta-cell glucose transporter (GLUT 2), proinsulin and islet amyloid polypeptide genes after prolonged fasting, insulin-induced hypoglycemia and dexamethasone treatment. Diabetologia 35:1125–1132CrossRefPubMed Koranyi L, Bourey R, Turk J, Mueckler M, Permutt MA (1992) Differential expression of rat pancreatic islet beta-cell glucose transporter (GLUT 2), proinsulin and islet amyloid polypeptide genes after prolonged fasting, insulin-induced hypoglycemia and dexamethasone treatment. Diabetologia 35:1125–1132CrossRefPubMed
28.
Zurück zum Zitat Mulder H, Ahrén B, Stridsberg M, Sundler F (1995) Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 38:395–402CrossRefPubMed Mulder H, Ahrén B, Stridsberg M, Sundler F (1995) Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rat islets following dexamethasone treatment. Diabetologia 38:395–402CrossRefPubMed
29.
Zurück zum Zitat Garlatti M, Daheshia M, Slater E et al. (1994) A functional glucocorticoid-responsive unit composed of two overlapping inactive receptor-binding sites: evidence for formation of a receptor tetramer. Mol Cell Biol 14:8007–8017CrossRefPubMedPubMedCentral Garlatti M, Daheshia M, Slater E et al. (1994) A functional glucocorticoid-responsive unit composed of two overlapping inactive receptor-binding sites: evidence for formation of a receptor tetramer. Mol Cell Biol 14:8007–8017CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Bretherton-Watt D, Gore N, Boam DS (1996) Insulin upstream factor 1 and a novel ubiquitous factor bind to the human islet amyloid polypeptide/amylin gene promoter. Biochem J 313:495–502CrossRefPubMedPubMedCentral Bretherton-Watt D, Gore N, Boam DS (1996) Insulin upstream factor 1 and a novel ubiquitous factor bind to the human islet amyloid polypeptide/amylin gene promoter. Biochem J 313:495–502CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Ortiz L, Zannini M, Di Lauro R, Santisteban P (1997) Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor. J Biol Chem 272:23334–23339CrossRefPubMed Ortiz L, Zannini M, Di Lauro R, Santisteban P (1997) Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor. J Biol Chem 272:23334–23339CrossRefPubMed
32.
Zurück zum Zitat Yamada K, Duong DT, Scott DK, Wang JC, Granner DK (1999) CCAAT/enhancer-binding protein beta is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter. J Biol Chem 274:5880–5887CrossRefPubMed Yamada K, Duong DT, Scott DK, Wang JC, Granner DK (1999) CCAAT/enhancer-binding protein beta is an accessory factor for the glucocorticoid response from the cAMP response element in the rat phosphoenolpyruvate carboxykinase gene promoter. J Biol Chem 274:5880–5887CrossRefPubMed
33.
Zurück zum Zitat Gasa R, Gomis R, Casamitjana R, Novials A (2001) High glucose concentration favors the selective secretion of islet amyloid polypeptide through a constitutive secretor pathway in human pancreatic islet. Pancreas 22:307–310CrossRefPubMed Gasa R, Gomis R, Casamitjana R, Novials A (2001) High glucose concentration favors the selective secretion of islet amyloid polypeptide through a constitutive secretor pathway in human pancreatic islet. Pancreas 22:307–310CrossRefPubMed
34.
Zurück zum Zitat Kahn SE, Verchere CB, D’Alessio DA et al. (1993) Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. Diabetologia 36:570–573CrossRefPubMed Kahn SE, Verchere CB, D’Alessio DA et al. (1993) Evidence for selective release of rodent islet amyloid polypeptide through the constitutive secretory pathway. Diabetologia 36:570–573CrossRefPubMed
Metadaten
Titel
Mutation at position −132 in the islet amyloid polypeptide (IAPP) gene promoter enhances basal transcriptional activity through a new CRE-like binding site
verfasst von
A. Novials
E. Mato
M. Lucas
C. Franco
M. Rivas
P. Santisteban
R. Gomis
Publikationsdatum
01.07.2004
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 7/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1439-y

Weitere Artikel der Ausgabe 7/2004

Diabetologia 7/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.